State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, China.
Jiangsu Key Laboratory of Advanced Organic Materials, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Molecules. 2019 Apr 30;24(9):1685. doi: 10.3390/molecules24091685.
Cyclooxygenase-2 (COX-2) as a rate-limiting metabolism enzyme of arachidonic acid has been found to be implicated in tumor occurrence, angiogenesis, metastasis as well as apoptosis inhibition, regarded as an attractive therapeutic target for cancer therapy. In our research, a series of dihydropyrazole derivatives containing benzo oxygen heterocycle and sulfonamide moieties were designed as highly potent and selective COX-2 inhibitors by computer-aided drug analysis of known COX-2 inhibitors. A total of 26 compounds were synthesized and evaluated COX-2 inhibition and pharmacological efficiency both in vitro and in vivo with multi-angle of view. Among them, compound exhibited most excellent anti-proliferation activities against SW620 cells with IC of 0.86 ± 0.02 µM than Celecoxib (IC = 1.29 ± 0.04 µM). The results favored our rational design intention and provides compound as an effective COX-2 inhibitor available for the development of colon tumor therapeutics.
环氧化酶-2(COX-2)作为花生四烯酸的限速代谢酶,已被发现与肿瘤发生、血管生成、转移以及细胞凋亡抑制有关,被认为是癌症治疗的一个有吸引力的治疗靶点。在我们的研究中,通过对已知 COX-2 抑制剂的计算机辅助药物分析,设计了一系列含有苯并氧杂环和磺酰胺部分的二氢吡唑衍生物,作为高效和选择性的 COX-2 抑制剂。共合成了 26 种化合物,并从多角度评估了它们在体外和体内对 COX-2 的抑制作用和药理活性。其中,化合物 对 SW620 细胞的增殖抑制活性最强,IC 为 0.86 ± 0.02 μM,优于塞来昔布(IC = 1.29 ± 0.04 μM)。结果符合我们的合理设计意图,并提供了化合物 作为一种有效的 COX-2 抑制剂,可用于开发结肠癌治疗药物。